(9;22)(q34;q11)易位出现在90%以上的慢性粒细胞白血病患者中,而在几乎5%至8%的慢性粒细胞白血病(CML)阳性病例中观察到变异/复杂易位。格列卫(甲磺酸伊马替尼)是首选断点簇区(BCR)/ABL靶向口服治疗,几乎在71%至80%的CML患者中产生完全反应。在诊断过程中对37例患者进行了全血细胞计数(CBC),然而,只有21个显示异常的CBC值被选择用于研究。使用骨髓样本进行核型分析研究21例CML患者的构象为9;22,然而,采用荧光原位杂交技术检测15例患者的BCR-ABL融合基因.在21名患者中,有17名患者出现Ph阳性(9;22)(q34;q11)易位。16例CML患者表现出标准易位,但只有CML患者表现出具有六个额外染色体的三向变异/复杂易位,52XX,t(1;9;22)(q23.3;q34;q11),+6,+8,i(9)(q10;q10),+18、+19、+21+der22t(9;22)(q34;q11))。在这里,我们报告了一个新的病例,6个额外的染色体与52XX的三向易位,t(1;9;22)(q23.3;q34;q11),+6,+8,i(9)(q10;q10),爆炸阶段+18、+19、+21+der22t(9;22)(q34;q11)。
(9;22) (q34; q11) translocation is appear in above ninety percent of chronic myelogenous leukemia patients while variant/complex translocations were observed in almost 5% to 8% chronic myelogenous leukemia (CML) positive cases. Gleevec (Imatinib Mesylate) is the first choice breakpoint cluster region (BCR)/ABL targeted oral therapy that produced a complete response almost in 71% to 80% of patients affected with CML. A complete blood count (CBC) of 37 patients was done during diagnosis, however only 21 showed abnormal CBC values which were selected for the study. Karyotyping study using bone marrow samples was performed on 21 CML patients for the conformation of 9;22, however, fluorescence in situ hybridisation was performed for the detection of the BCR-ABL fusion gene of 15 patients. Out of 21, 17 patients showed Ph-positive (9;22) (q34; q11) translocation. Sixteen CML patients showed standard translocation however only CML patients showed a three-way variant/complex translocation with six additional chromosomes, 52XX, t(1;9;22) (q23.3;q34;q11),+6,+8, i(9)(q10;q10), +18,+19,+21 + der22 t(9;22)(q34;q11)). Here we report we report a novel
case of six additional chromosomes with the three-way translocation of 52XX, t(1;9;22) (q23.3;q34;q11),+6,+8, i(9)(q10;q10), +18,+19,+21 + der22 t(9;22)(q34;q11) in blast phase.